Workflow
梅花生物(600873) - 2017 Q1 - 季度财报

Financial Performance - Net profit attributable to shareholders was CNY 341,433,631.67, representing a significant increase of 53.98% year-on-year[6]. - Operating revenue for the period reached CNY 2,739,108,531.41, reflecting a growth of 3.63% compared to the same period last year[6]. - Basic earnings per share rose to CNY 0.11, an increase of 57.14% from CNY 0.07 in the previous year[6]. - The company's net profit for Q1 2017 was CNY 348.73 million, an increase of 54.44% compared to CNY 225.80 million in the same period last year[10]. - The total profit for the current period was ¥406,225,054.45, up from ¥258,914,743.18 in the previous period, reflecting a growth of 56.93%[23]. - Net profit for the current period was ¥348,729,307.14, representing a 54.31% increase from ¥225,801,961.51 in the previous period[23]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 16,809,158,078.16, a decrease of 1.02% compared to the end of the previous year[6]. - Current liabilities decreased from ¥4,586,789,027.71 to ¥4,063,878,847.41, a reduction of about 11.43%[18]. - Total liabilities decreased from ¥7,686,184,310.37 to ¥7,163,628,299.02, a decline of about 6.8%[18]. - Owner's equity increased from ¥9,296,827,792.00 to ¥9,645,529,779.14, an increase of approximately 3.75%[18]. - Total current assets decreased from ¥5,545,522,597.05 to ¥4,242,366,298.87, a decline of approximately 23.5%[20]. - Total liabilities and owner's equity decreased from ¥14,812,557,123.23 to ¥13,534,726,931.94, a decline of approximately 8.6%[21]. Cash Flow - Net cash flow from operating activities was CNY 305,550,291.38, down 8.10% from CNY 332,471,348.53 in the same period last year[6]. - Cash flow from operating activities amounted to ¥2,691,587,772.04, an increase from ¥2,289,478,547.97 in the previous period[28]. - Total cash inflow from operating activities was ¥2,750,620,459.28, up 15.4% from ¥2,384,009,799.63 year-over-year[29]. - Cash outflow from operating activities increased to ¥2,445,070,167.90, compared to ¥2,051,538,451.10 in the same period last year, reflecting a rise of 19.2%[29]. - The net cash flow from investing activities was -¥96,320,374.03, worsening from -¥20,125,084.85 in the previous year[29]. - The ending cash and cash equivalents balance was ¥2,262,271,757.28, down from ¥778,727,709.09 in the previous year[30]. Shareholder Information - The total number of shareholders at the end of the reporting period was 162,009[9]. - The largest shareholder, Meng Qingshan, holds 27.48% of the shares, with 423,720,000 shares pledged[9]. - The company’s cash dividend distribution for 2016 was CNY 0.30 per share, totaling CNY 932.47 million[12]. Investments and Expenditures - The company completed an investment of CNY 349 million in Liaoning Aimei Biological Vaccine Technology Group, acquiring a 6.3291% stake[12]. - The total amount of prepaid accounts increased by 60.62% to CNY 180.67 million, primarily due to increased payments for raw materials[10]. - The company reported a significant increase in investment income, rising by 513.76% to CNY 13.86 million, attributed to higher financial investment returns[10]. - The company’s construction in progress increased by 43.35% to CNY 186.81 million, mainly due to ongoing technical transformation projects[10]. - The company’s available-for-sale financial assets rose by 118.50% to CNY 643.52 million, due to new equity investments in Aimei[10]. Operating Costs and Expenses - Total operating costs decreased to ¥2,398,947,800.37, down 0.36% from ¥2,407,628,774.09 in the previous period[23]. - The company reported a significant increase in sales expenses, which rose to ¥238,826,069.15 from ¥189,589,780.07, marking a 25.92% increase[23].